We used everolimus (RAD001) to inhibit mTOR, alone or in combination with anti-EGFR drugs gefitinib or cetuximab, on human cancer cell lines sensitive and resistant to EGFR inhibitors, both in ...

In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and ...

Currently, two mTOR inhibitors, temsirolimus and everolimus, are approved for the treatment of patients with advanced renal cell carcinoma (RCC). Clinical trials comparing single-agent ...

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain ...

ORLANDO, Fla.—The use of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, is feasible and efficacious for the prevention of graft-versus-host disease (GVHD) in a series of patients ...

To provide further rationale for using the mTOR inhibitor everolimus in MCL, we evaluated mTOR activity in three mantle cell lines Jeko, Mino and Granta by measuring the phosphorylation profile of ...

In cells, rapamycin and other rapalogs such as everolimus suppress geroconversion from quiescence to senescence. Rapamycin inhibits some, but not all, activities of mTOR. Recently we and others ...

A second study looked at everolimus, another mTOR pathway inhibitor, in a slightly older population of ADPKD patients (mean age, 44.5 years). Patients (n = 433) were randomized in a 1:1 manner to ...

Most patients with a nonmalignant form of kidney tumor had significant tumor shrinkage with the mammalian target of rapamycin (mTOR) inhibitor everolimus (Afinitor), a small multicenter clinical ...

WOODCLIFF LAKE, N.J., Nov. 7, 2020 /PRNewswire/ -- Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of tw ...